Elutia Announces Strong Third Quarter Results, Accelerating Toward Full Launch of EluPro® Antibiotic-Eluting BioEnvelope in 2025
Provided By GlobeNewswire
Last update: Nov 14, 2024
Over 100 EluPro VAC Submissions and 19% SimpliDerm Growth Drive Momentum into 2025
SILVER SPRING, Md., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, today provided a business update and financial results for the third quarter ended September 30, 2024.
Read more at globenewswire.com
